656804-75-0

Upstream product

• 656804-74-9 5-bromo-2-(2,4-dichlorophenyl)-6-fluoro-2-(4-fluorophenyl)benzo[1,3]dioxole 
• 124-38-9 carbon dioxide 

Downstream Products

• 656804-84-1 (R)-[2-(2,4-dichlorophenyl)-6-fluoro-2-(4-methoxyphenyl)benzo[1,3]dioxol-5-yl]morpholin-4-ylmethanone 
• 656804-86-3 (S)-[2-(2,4-dichlorophenyl)-6-fluoro-2-(4-methoxyphenyl)benzo[1,3]dioxol-5-yl]morpholin-4-ylmethanone 
• 656804-72-7 [2-(2,4-dichloro-phenyl)-6-fluoro-2-(4-fluoro-phenyl)-benzo[1,3]dioxol-5-yl]-morpholin-4-yl-methanone 

Relevant academic research and scientific papers

Benzodioxoles: Novel cannabinoid-1 receptor inverse agonists for the treatment of obesity

The application of the evolutionary fragment-based de novo design tool TOPology Assigning System (TOPAS), starting from a known CB1R (CB-1 receptor) ligand, followed by further refinement principles, including pharmacophore compliance, chemical tractabili

Stereospecifically substituted benzo[1,3]dioxolyl derivatives

The present invention relates to compounds of formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are

NOVEL BENZODIOXOLES

The present invention relates to compound of formula (I) Wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases, which are associated with the modulation of CB1 receptors.